Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELUNE study of secukinumab versus placebo in active lupus nephritis
PACTR202211748997845Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing Secukinumab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Complete Renal Response. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
secukinumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on PACTR202211748997845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202211748997845.